| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6e29526f284c0155fd79806c9dd5a1c7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2506-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2533-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-603
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-604
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-602
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-608
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-606
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-115
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2500-25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2502-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-60 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0696 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-074 |
| filingDate |
2019-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_56aa6ed7fc274ab4a2eb2633e6322386
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dcd82f466e52d4302d1b9377b3b72ffe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e998e930567c8bd7e484dacc5b2de486 |
| publicationDate |
2020-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10745671-B2 |
| titleOfInvention |
Efficient method for reprogramming blood to induced pluripotent stem cells |
| abstract |
Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11572545-B2 |
| priorityDate |
2016-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |